{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:37:16Z","timestamp":1772213836160,"version":"3.50.1"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto Nacional de Salud","award":["OI-35-21"],"award-info":[{"award-number":["OI-35-21"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The administration of a third (booster) dose of COVID-19 vaccines in Peru initially employed the BNT162b2 (Pfizer) mRNA vaccine. The national vaccination program started with healthcare workers (HCW) who received BBIBP-CorV (Sinopharm) vaccine as primary regimen and elderly people previously immunized with BNT162b2. This study evaluated the reactogenicity and immunogenicity of the \u201cbooster\u201d dose in these two groups in Lima, Peru.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective cohort study, recruiting participants from November to December of 2021 in Lima, Peru. We evaluated immunogenicity and reactogenicity in HCW and elderly patients previously vaccinated with either two doses of BBIBP-CorV (heterologous regimen) or BTN162b2 (homologous regimen). Immunogenicity was measured by anti-SARS-CoV-2 IgG antibody levels immediately before boosting dose and 14 days later. IgG geometric means (GM) and medians were obtained, and modeled using ANCOVA and quantile regressions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The GM of IgG levels increased significantly after boosting: from 28.5\u00b15.0 AU\/mL up to 486.6\u00b11.2 AU\/mL (p&lt;0.001) which corresponds to a 17-fold increase. The heterologous vaccine regimen produced higher GM of post-booster anti-SARS-CoV-2 IgG levels, eliciting a 13% increase in the geometric mean ratio (95%CI: 1.02\u20131.27) and a median difference of 92.3 AU\/ml (95%CI: 24.9\u2013159.7). Both vaccine regimens were safe and well tolerated. Previous COVID-19 infection was also associated with higher pre and post-booster IgG GM levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although both boosting regimens were highly immunogenic, two doses of BBIBP-CorV boosted with BTN162b2 produced a stronger IgG antibody response than the homologous BNT162b2 regimen in the Peruvian population. Additionally, both regimens were mildly reactogenic and well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0268419","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T13:25:54Z","timestamp":1666013154000},"page":"e0268419","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0948-0114","authenticated-orcid":true,"given":"Natalia","family":"Vargas-Herrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3637-2052","authenticated-orcid":true,"given":"Manuel","family":"Fern\u00e1ndez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor E.","family":"Cabezudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Soto-Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-088X","authenticated-orcid":true,"given":"Gilmer","family":"Sol\u00eds-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Escobar-Agreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Silva-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Pampa-Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Bado-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lely","family":"Solari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-1962","authenticated-orcid":true,"given":"Roger V.","family":"Araujo-Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"pone.0268419.ref001","unstructured":"WHO\/PAHO\u2014Respuesta a la emergencia por COVID-19 en Per\u00fa | Pan-American Health Organization [Internet]. [Cited January 25th 2022]. https:\/\/www.paho.org\/es\/respuesta-emergencia-por-covid-19-peru"},{"key":"pone.0268419.ref002","unstructured":"Johns Hopkins University of Medicine. Peru\u2014COVID-19 Overview\u2014Johns Hopkins [Internet]. Johns Hopkins Coronavirus Resource Center. [Cited March 22nd 2022]. https:\/\/coronavirus.jhu.edu\/region\/peru"},{"key":"pone.0268419.ref003","article-title":"Some lessons that Peru did not learn before the second wave of COVID\u201019","author":"P Herrera\u2010A\u00f1azco","year":"2021","journal-title":"Int J Health Plann Manage"},{"key":"pone.0268419.ref004","first-page":"106","article-title":"Supervivencia de los trabajadores de salud infectados por SARS-CoV-2 en el contexto de la vacunaci\u00f3n contra la COVID-19 en el Per\u00fa","author":"S Escobar-Agreda","year":"2021","journal-title":"Fac Med Per\u00fa"},{"key":"pone.0268419.ref005","unstructured":"RESOLUCION-MINISTERIAL-No-488-2021-MINSA-21-042269-005.pdf [Internet]. [Cited January 25th 2022]. https:\/\/www.dge.gob.pe\/portalnuevo\/wp-content\/uploads\/2020\/04\/RESOLUCION-MINISTERIAL-N%C2%BA-488-2021-MINSA-21-042269-005.pdf"},{"key":"pone.0268419.ref006","unstructured":"Ministerio de Salud\u2014Peru. Vacuna COVID-19 en el Per\u00fa [Internet]. REUNIS\u2014Repositorio \u00danico Nacional de Informaci\u00f3n en Salud. 2022 [Cited January 25th 2022]. https:\/\/www.minsa.gob.pe\/reunis\/data\/vacunas-covid19.asp"},{"issue":"2","key":"pone.0268419.ref007","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.healun.2021.08.010","article-title":"Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience","volume":"41","author":"Y Peled","year":"2022","journal-title":"J Heart Lung Transplant. February"},{"issue":"3","key":"pone.0268419.ref008","doi-asserted-by":"crossref","first-page":"e0247711","DOI":"10.1371\/journal.pone.0247711","article-title":"Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan","volume":"16","author":"R Yokoyama","year":"2021","journal-title":"PLoS ONE. March"},{"key":"pone.0268419.ref009","unstructured":"National Cancer Institute\u2014Division of cancer Treatment & Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP [Internet]. [Cited April 27th 2022]. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"pone.0268419.ref010","doi-asserted-by":"crossref","unstructured":"Harrell, F.E. Regression Modeling Strategies: With applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.","DOI":"10.1007\/978-1-4757-3462-1"},{"issue":"2","key":"pone.0268419.ref011","doi-asserted-by":"crossref","first-page":"e0263468","DOI":"10.1371\/journal.pone.0263468","article-title":"Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection\u2014A comparative study from Novi Sad, Serbia","volume":"17","author":"V Petrovi\u0107","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pone.0268419.ref012","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/vaccines10040502","article-title":"Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection","volume":"10","author":"M Hueda-Zavaleta","year":"2022","journal-title":"Vaccines"},{"issue":"46","key":"pone.0268419.ref013","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1016\/j.vaccine.2021.10.007","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon","volume":"39","author":"R Moghnieh","year":"2021","journal-title":"Vaccine. November"},{"key":"pone.0268419.ref014","doi-asserted-by":"crossref","unstructured":"Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies [Internet]. medRxiv January 2022 [Cited February 16th 2022]. http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.01.14.22269289","DOI":"10.1101\/2022.01.14.22269289"},{"issue":"10324","key":"pone.0268419.ref015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"SA Costa Clemens","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"pone.0268419.ref016","doi-asserted-by":"crossref","first-page":"2029111","DOI":"10.1080\/21645515.2022.2029111","article-title":"Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study","volume":"18","author":"N Wanlapakorn","year":"2022","journal-title":"Hum Vaccines Immunother. December"},{"issue":"11","key":"pone.0268419.ref017","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and Heterologous Covid-19 Booster Vaccinations","volume":"386","author":"RL Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0268419.ref018","article-title":"COVID\u201019 vaccines mix\u2010and\u2010match: The concept, the efficacy and the doubts","author":"R Rashedi","year":"2021","journal-title":"J Med Virol"},{"issue":"29\u201330","key":"pone.0268419.ref019","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.vaccine.2008.04.073","article-title":"Heterologous HA DNA vaccine prime\u2014inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses","volume":"26","author":"S Wang","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"pone.0268419.ref020","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice","volume":"12","author":"AJ Spencer","year":"2021","journal-title":"Nat Commun"},{"key":"pone.0268419.ref021","doi-asserted-by":"crossref","unstructured":"Gro\u00df R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 1 de enero de 2021;2021.05.30.21257971.","DOI":"10.1101\/2021.05.30.21257971"},{"issue":"9","key":"pone.0268419.ref022","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"J Barros-Martins","year":"2021","journal-title":"Nat Med. septiembre de"},{"issue":"10318","key":"pone.0268419.ref023","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"APS Munro","year":"2021","journal-title":"The Lancet"},{"issue":"15","key":"pone.0268419.ref024","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel","volume":"385","author":"YM Bar-On","year":"2021","journal-title":"N Engl J Med"},{"issue":"6549","key":"pone.0268419.ref025","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.abj2258","article-title":"Hybrid immunity","volume":"372","author":"Shane Crotty","year":"2021","journal-title":"Science"},{"issue":"5","key":"pone.0268419.ref026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jogn.2020.08.001","article-title":"Sex-Based Vaccine Response in the Context of COVID-19","volume":"49","author":"PR McCartney","year":"2020","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"32","key":"pone.0268419.ref027","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"KA Earle","year":"2021","journal-title":"Vaccine. July"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:23:29Z","timestamp":1728156209000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268419"}},"subtitle":[],"editor":[{"given":"Daniela Flavia","family":"Hozbor","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,17]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268419","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.01.22274548","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,17]]}}}